To be or not to be… treated with initial combination therapy, that is the (PAH) question
- PMID: 35654453
- DOI: 10.1183/13993003.00390-2022
To be or not to be… treated with initial combination therapy, that is the (PAH) question
Conflict of interest statement
Conflict of interest: O. Sitbon reports grants from Acceleron, Janssen, GSK and MSD; consulting fees from Gossamer Bio, Janssen and MSD; lecture honoraria from AOP Orphan, Janssen, Ferrer and MSD; and participation on advisory boards for Acceleron, Janssen and MSD, all outside the submitted work. A. Boucly reports lecture honoraria from Janssen and MSD, outside the submitted work. M. Humbert reports grants and consulting fees from Acceleron, Janssen and Merck; lecture honoraria from AOP, Janssen and Merck; and participation on advisory boards for Acceleron, Janssen, Merck and United Therapeutics, all outside the submitted work.
Comment on
-
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.Eur Respir J. 2022 Jun 2;59(6):2101552. doi: 10.1183/13993003.01552-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34675044 Free PMC article.
-
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.Eur Respir J. 2022 Jun 2;59(6):2102024. doi: 10.1183/13993003.02024-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34675047 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources